Apr 25, 2013 9:00am EDT Lixte Biotechnology Announces Initiation Of A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
Jul 31, 2012 9:00am EDT Lixte Biotechnology Holdings Announces Increased Funding And FDA Allowance To Conduct A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
May 01, 2012 12:00pm EDT Lixte Biotechnology Holdings Announces Submission of an IND to the FDA for Approval of a Clinical Trial of LB-100, a First-in-Class, Anti-Cancer Compound
Apr 04, 2012 9:30am EDT Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
Jan 09, 2012 9:00am EST Lixte Biotechnology Holdings Announces Issuance of U.S. Patent for Agents for the Treatment of Neurodegenerative Diseases
Dec 19, 2011 9:00am EST Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease
Sep 22, 2011 9:00am EDT Lixte Biotechnology Holdings Announces Issuance of U.S. Patent for Lead Anti-Cancer Compound
Mar 02, 2011 10:39am EST Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
